These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20698819)

  • 1. Nitric oxide: target for therapeutic strategies in Alzheimer's disease.
    Fernandez AP; Pozo-Rodrigalvarez A; Serrano J; Martinez-Murillo R
    Curr Pharm Des; 2010; 16(25):2837-50. PubMed ID: 20698819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of NMDAR2B in an inflammatory model of Alzheimer's disease: modulation by NOS inhibitors.
    Maher A; El-Sayed NS; Breitinger HG; Gad MZ
    Brain Res Bull; 2014 Oct; 109():109-16. PubMed ID: 25454121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-β decreases nitric oxide production in cultured retinal neurons: a possible mechanism for synaptic dysfunction in Alzheimer's disease?
    Oliveira LT; Louzada PR; de Mello FG; Ferreira ST
    Neurochem Res; 2011 Jan; 36(1):163-9. PubMed ID: 20936504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-amyloid treatments in Alzheimer's disease.
    Sapra M; Kim KY
    Recent Pat CNS Drug Discov; 2009 Jun; 4(2):143-8. PubMed ID: 19519562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology.
    Lüth HJ; Holzer M; Gärtner U; Staufenbiel M; Arendt T
    Brain Res; 2001 Sep; 913(1):57-67. PubMed ID: 11532247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental research on nitric oxide and the therapy of Alzheimer disease: a challenging bridge.
    Siciliano R; Barone E; Calabrese V; Rispoli V; Butterfield DA; Mancuso C
    CNS Neurol Disord Drug Targets; 2011 Nov; 10(7):766-76. PubMed ID: 21999733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy.
    Zhihui Q
    Future Med Chem; 2013 Aug; 5(12):1451-68. PubMed ID: 23919554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of nitric oxide in Alzheimer's disease.
    Wang L; Lu D; Wang X; Wang Z; Li W; Chen G
    Med Gas Res; 2024 Dec; 14(4):186-191. PubMed ID: 39073326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inducible nitric oxide synthase induces beta-amyloid neurotoxicity in vivo].
    Liu H; Chen JP; Zhang WQ
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2002 Nov; 18(4):329-32. PubMed ID: 21174802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
    León R; Garcia AG; Marco-Contelles J
    Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment.
    Gazova Z; Soukup O; Sepsova V; Siposova K; Drtinova L; Jost P; Spilovska K; Korabecny J; Nepovimova E; Fedunova D; Horak M; Kaniakova M; Wang ZJ; Hamouda AK; Kuca K
    Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):607-619. PubMed ID: 27865910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive enhancement therapy for Alzheimer's disease. The way forward.
    Parnetti L; Senin U; Mecocci P
    Drugs; 1997 May; 53(5):752-68. PubMed ID: 9129864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity.
    Law A; Gauthier S; Quirion R
    Br J Pharmacol; 2001 Aug; 133(7):1114-24. PubMed ID: 11487523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The redox chemistry of the Alzheimer's disease amyloid beta peptide.
    Smith DG; Cappai R; Barnham KJ
    Biochim Biophys Acta; 2007 Aug; 1768(8):1976-90. PubMed ID: 17433250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism.
    Akama KT; Albanese C; Pestell RG; Van Eldik LJ
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5795-800. PubMed ID: 9576964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Molecule Natural Products and Alzheimer's Disease.
    Wu X; Cai H; Pan L; Cui G; Qin F; Li Y; Cai Z
    Curr Top Med Chem; 2019; 19(3):187-204. PubMed ID: 30714527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pin1, endothelial nitric oxide synthase, and amyloid-β form a feedback signaling loop involved in the pathogenesis of Alzheimer's disease, hypertension, and cerebral amyloid angiopathy.
    Wang JZ; Zhu WD; Xu ZX; Du WT; Zhang HY; Sun XW; Wang XH
    Med Hypotheses; 2014 Feb; 82(2):145-50. PubMed ID: 24332564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's disease: an overview of current and emerging therapeutic strategies.
    Jacobsen JS
    Curr Top Med Chem; 2002 Apr; 2(4):343-52. PubMed ID: 11966458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.